Naranbhai et al.
2022
Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in patients with cancer: the CANVAX cohort study
Hauser et al.
2021
Safety of ocrelizumab in patients with relapsing and primary progressive multiple sclerosis
Simpson et al.
2023
Efficacy and safety of lebrikizumab in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis: a randomized clinical trial (ADhere)
Wood et al.
2022
Protocol design and synopsis: omalizumab as monotherapy and as adjunct therapy to multiallergen OIT in children and adults with food allergy (OUtMATCH)
Vieujean et al.
2025
Understanding the therapeutic toolkit for inflammatory bowel disease
Johns et al.
2021
Checkpoint inhibitor immunotherapy toxicity and overall survival among older adults with advanced cancer
Carrascosa et al.
2014
Clinical relevance of immunogenicity of biologics in psoriasis: implications for treatment strategies
Villar et al.
2012
Immunological markers of optimal response to natalizumab in multiple sclerosis
Hariprasad et al.
2022
An introduction to biosimilars for the treatment of retinal diseases: a narrative review
TWI860531B
(zh )
2024-11-01
用於預測細胞激素釋放症候群之多變量模型
JP2018154648A
(ja )
2018-10-04
Il−4rアンタゴニストを投与することによるアトピー性皮膚炎を処置するための方法
Kearns et al.
2023
A root cause analysis to identify the mechanistic drivers of immunogenicity against the anti-VEGF biotherapeutic brolucizumab
Lin et al.
2005
Successful treatment of recalcitrant pemphigus vulgaris and pemphigus vegetans with etanercept and carbon dioxide laser
JP2021503476A
(ja )
2021-02-12
Il−17アンタゴニストを用いて化膿性汗腺炎を治療すること
Cubberley et al.
2025
Global RA treatment recommendations: an update from the various international societies
Zinger et al.
2024
Long-term effectiveness and safety of risankizumab in patients with Crohn’s disease
Xie et al.
2019
Sustained clinical remission of rheumatoid arthritis and its predictive factors in an unselected adult Chinese population from 2009 to 2018
Bresciani et al.
2023
Caspr1 antibodies autoimmune paranodopathy with severe tetraparesis: potential relevance of antibody titers in monitoring treatment response
Paltiel et al.
2008
Immediate type I hypersensitivity response implicated in worsening injection site reactions to adalimumab
Shi et al.
2025
Fast-acting treatment of myasthenic crisis with efgartigimod from the perspective of the Neuro intensive care unit
Yegya-Raman et al.
2023
Utilization and factors precluding receipt of checkpoint inhibitor consolidation for stage III NSCLC in a large US academic health system
Wallace et al.
2023
Lowering expectations: glucocorticoid tapering among veterans with rheumatoid arthritis achieving low disease activity on stable biologic therapy
Al-Sawaf et al.
2023
Pirtobrutinib versus venetoclax in covalent Bruton tyrosine kinase inhibitor-pretreated chronic lymphocytic leukemia: a matching-adjusted indirect comparison
Giossi et al.
2022
Anti-Spike IgG in multiple sclerosis patients after BNT162b2 vaccine: An exploratory case-control study in Italy
Swain et al.
2023
Incidence and severity of anaphylaxis and hypersensitivity in trials of intravenous pertuzumab plus trastuzumab or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection for HER2-positive breast cancer